BRASKEM SA-CLASS A- ADR (BAK)

US1055321053 - ADR

8.18  -0.16 (-1.92%)

After market: 8.2 +0.02 (+0.24%)

Fundamental Rating

1

Overall BAK gets a fundamental rating of 1 out of 10. We evaluated BAK against 85 industry peers in the Chemicals industry. BAK may be in some trouble as it scores bad on both profitability and health. BAK does not seem to be growing, but still is valued expensively.



1

1. Profitability

1.1 Basic Checks

BAK had negative earnings in the past year.
In the past year BAK has reported a negative cash flow from operations.
In multiple years BAK reported negative net income over the last 5 years.
In the past 5 years BAK always reported a positive cash flow from operatings.

1.2 Ratios

BAK's Return On Assets of -5.12% is on the low side compared to the rest of the industry. BAK is outperformed by 78.82% of its industry peers.
BAK has a Return On Equity of -93.87%. This is amonst the worse of the industry: BAK underperforms 92.94% of its industry peers.
Industry RankSector Rank
ROA -5.12%
ROE -93.87%
ROIC N/A
ROA(3y)2.32%
ROA(5y)1.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of BAK has declined.
BAK has a worse Gross Margin (2.66%) than 88.24% of its industry peers.
In the last couple of years the Gross Margin of BAK has declined.
BAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 2.66%
OM growth 3Y-5.67%
OM growth 5Y-20.61%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.5%
GM growth 5Y-14.73%

1

2. Health

2.1 Basic Checks

BAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BAK remains at a similar level compared to 1 year ago.
The number of shares outstanding for BAK remains at a similar level compared to 5 years ago.
BAK has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 0.98, we must say that BAK is in the distress zone and has some risk of bankruptcy.
BAK's Altman-Z score of 0.98 is on the low side compared to the rest of the industry. BAK is outperformed by 78.82% of its industry peers.
A Debt/Equity ratio of 10.77 is on the high side and indicates that BAK has dependencies on debt financing.
BAK's Debt to Equity ratio of 10.77 is on the low side compared to the rest of the industry. BAK is outperformed by 96.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.77
Debt/FCF N/A
Altman-Z 0.98
ROIC/WACCN/A
WACC8.94%

2.3 Liquidity

BAK has a Current Ratio of 1.54. This is a normal value and indicates that BAK is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.54, BAK is doing worse than 74.12% of the companies in the same industry.
BAK has a Quick Ratio of 1.03. This is a normal value and indicates that BAK is financially healthy and should not expect problems in meeting its short term obligations.
BAK has a worse Quick ratio (1.03) than 69.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.03

3

3. Growth

3.1 Past

BAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -333.36%.
The Revenue for BAK has decreased by -31.09% in the past year. This is quite bad
BAK shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.40% yearly.
EPS 1Y (TTM)-333.36%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-119.57%
Revenue 1Y (TTM)-31.09%
Revenue growth 3Y22.64%
Revenue growth 5Y14.4%
Revenue growth Q2Q-34.31%

3.2 Future

The Earnings Per Share is expected to grow by 83.56% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -5.53% on average over the next years.
EPS Next Y-1058.25%
EPS Next 2Y-118.08%
EPS Next 3Y83.56%
EPS Next 5YN/A
Revenue Next Year-27.78%
Revenue Next 2Y-12.29%
Revenue Next 3Y-5.53%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

BAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BAK indicates a slightly more expensive valuation: BAK is more expensive than 60.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.48

4.3 Compensation for Growth

BAK's earnings are expected to grow with 83.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-118.08%
EPS Next 3Y83.56%

0

5. Dividend

5.1 Amount

BAK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BRASKEM SA-CLASS A- ADR

NYSE:BAK (2/23/2024, 7:04:00 PM)

After market: 8.2 +0.02 (+0.24%)

8.18

-0.16 (-1.92%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.26B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.12%
ROE -93.87%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 2.66%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 10.77
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.54
Quick Ratio 1.03
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-333.36%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1058.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-31.09%
Revenue growth 3Y22.64%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y